CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, November 6th, to ...

Core Insights - Apyx Medical Corporation has initiated the nationwide commercial launch of the AYON Body Contouring System, with a focus on expanding its capabilities to include power liposuction through a new 510(k) premarket notification to the FDA [2][3] - The AYON system is designed to integrate various body contouring procedures into a single platform, enhancing workflow for surgeons and potentially improving patient outcomes [3][5] - Apyx Medical is hosting a virtual event on October 14, 2025, featuring key opinion leaders to discuss the commercial launch and advancements of the AYON system [4] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with products like Renuvion and the AYON Body Contouring System [5] - The AYON Body Contouring System is FDA-cleared and combines multiple functionalities, including fat removal and tissue contraction, aimed at providing comprehensive body contouring treatments [5] - The company has received positive feedback from early adopters of the AYON system, indicating strong market interest and potential for growth [3]

Core Insights - Apyx Medical Corporation announced a virtual key opinion leader event to discuss the commercial launch of its new AYON Body Contouring System on October 14, 2025 [1] - The AYON Body Contouring System is the first FDA cleared all-in-one platform for aesthetic surgical suites, integrating multiple capabilities for improved surgical outcomes [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and AYON in the cosmetic surgery market [5] - The company’s Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical publications [5] Key Opinion Leader Event - The event will feature Dr. Paul Vanek, a renowned plastic surgeon, who will discuss the AYON Body Contouring System alongside company management [1][2] - A live Q&A session will follow the formal presentations, allowing for direct engagement with attendees [3] Product Features - The AYON Body Contouring System combines precision, versatility, and innovation, designed to streamline procedures and maximize patient outcomes [2] - It integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, setting a new standard in surgical care [2] Leadership Profile - Dr. Paul Vanek is recognized for his extensive experience in the field, having built a successful practice and contributed to various medical innovations [4] - He has held leadership roles in hospital systems and has been involved in numerous philanthropic efforts [4]

Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion® and the AYON Body Contouring System™ for the cosmetic surgery market, as well as J-Plasma® for the hospital surgical market [3] - The company's technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical publications [3] Upcoming Events - Management will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA [1] - The President and CEO, Charlie Goodwin, along with CFO, Matt Hill, will engage in a fireside chat at 4:00 PM ET and will hold one-on-one meetings with investors throughout the day [2] Investor Relations - For further inquiries, the investor relations contact is Jeremy Feffer, Managing Director at LifeSci Advisors, reachable at 212-915-2568 or via email [4]

Core Viewpoint - Apyx Medical Corporation will release its financial results for Q2 of fiscal year 2025 on August 7, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 4:30 p.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 35370 [2] - A live webcast of the call will be available on the company's website and will be archived for future reference [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology is utilized in both cosmetic surgery and hospital surgical markets, providing surgeons with controlled heat to achieve desired results [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, showcasing the company's commitment to clinical validation [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Insights - Apyx Medical Corporation is showcasing its Renuvion technology at Miami Swim Week, emphasizing real patient transformations and the empowerment of individuals through body contouring solutions [1][2][3] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion, and the AYON Body Contouring System™ [5] - The company provides innovative products that enable surgeons to deliver controlled heat to tissue, supported by over 90 clinical documents [5] Product Highlights - Renuvion combines helium plasma and radiofrequency energy to achieve tissue contraction and collagen remodeling, making it a trusted tool for plastic surgeons globally [3] - The technology addresses loose skin concerns, which affect millions, offering a solution with minimal downtime [2][3] Marketing and Branding - The company aims to redefine beauty standards by highlighting real patient journeys and encouraging self-acceptance through its marketing efforts at major cultural events [3] - Apyx Medical's mission extends beyond aesthetics, focusing on restoring confidence to individuals struggling with loose skin [3]

Core Viewpoint - Apyx Medical Corporation has received FDA 510(k) clearance for the AYON Body Contouring System, marking a significant advancement in aesthetic surgical technology and is set to launch commercially in the second half of 2025 [1][6]. Group 1: Product Overview - The AYON Body Contouring System is an all-in-one platform designed for body contouring, integrating fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities [3][4]. - It features LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, aiming to improve surgical precision and patient outcomes [3][6]. - The system is expected to revolutionize body contouring procedures and is backed by Apyx Medical's expertise and evidence-based design [3][6]. Group 2: Market Context - The aesthetics market is projected to see a rapid increase in body contouring procedures, particularly as over 15 million patients using GLP-1 drugs experience significant weight loss and seek solutions for loose skin [6]. - The initial FDA clearance for AYON covers various aesthetic treatments, including ultrasound-assisted liposuction and electrocoagulation for tissue removal, with plans for further indications like power liposuction [4][5]. Group 3: Company Background - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Platform Technology products marketed as Renuvion and the AYON Body Contouring System [7]. - The effectiveness of Renuvion and J-Plasma technologies is supported by over 90 clinical documents, showcasing the company's commitment to innovation in surgical solutions [7].